Study on the Safety, Tolerability, and Preliminary Efficacy of 161Tb-NYM032 in Patients with Metastatic Castration-Resistant Prostate Cancer

NCT06827080 PHASE1, PHASE2 NOT_YET_RECRUITING

161Tb-NYM032 is a radiopharmaceutical labeled with a PSMA ligand, used for the treatment of metastatic castration-resistant prostate cancer, which is needed for clinical trial to be conducted.

Details

Lead sponsor	Zhengguo Chen
Phase	PHASE1, PHASE2
Status	NOT_YET_RECRUITING
Enrolment	15
Start date	Tue Feb 11 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Tue Dec 01 2026 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Metastatic Castration-resistant Prostate Cancer, MCRPC
• Cancer

Interventions

• 30 mCi NYMO32
• 50 mCi NYMO32
• 80 mCi NYMO32
• 130 mCi NYMO32
• 200 mCi NYMO32